These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 7788147)

  • 1. The therapeutic effects of an engineered human anti-tumour necrosis factor alpha antibody (CDP571) in rheumatoid arthritis.
    Rankin EC; Choy EH; Kassimos D; Kingsley GH; Sopwith AM; Isenberg DA; Panayi GS
    Br J Rheumatol; 1995 Apr; 34(4):334-42. PubMed ID: 7788147
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The engineered human anti-tumor necrosis factor-alpha antibody CDP571 inhibits inflammatory pathways but not T cell activation in patients with rheumatoid arthritis.
    Choy EH; Rankin EC; Kassimos D; Vetterlein O; Garyfallos A; Ravirajan CT; Sopwith M; Eastell R; Kingsley GH; Isenberg DA; Panayi GS
    J Rheumatol; 1999 Nov; 26(11):2310-7. PubMed ID: 10555883
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CDP571, a humanised monoclonal antibody to tumour necrosis factor alpha, for moderate to severe Crohn's disease: a randomised, double blind, placebo controlled trial.
    Sandborn WJ; Feagan BG; Radford-Smith G; Kovacs A; Enns R; Innes A; Patel J
    Gut; 2004 Oct; 53(10):1485-93. PubMed ID: 15361500
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomised controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn's disease.
    Stack WA; Mann SD; Roy AJ; Heath P; Sopwith M; Freeman J; Holmes G; Long R; Forbes A; Kamm MA
    Lancet; 1997 Feb; 349(9051):521-4. PubMed ID: 9048788
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CDP571, a humanized antibody to human tumor necrosis factor-alpha: safety, pharmacokinetics, immune response, and influence of the antibody on cytokine concentrations in patients with septic shock. CPD571 Sepsis Study Group.
    Dhainaut JF; Vincent JL; Richard C; Lejeune P; Martin C; Fierobe L; Stephens S; Ney UM; Sopwith M
    Crit Care Med; 1995 Sep; 23(9):1461-9. PubMed ID: 7664546
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis.
    Elliott MJ; Maini RN; Feldmann M; Kalden JR; Antoni C; Smolen JS; Leeb B; Breedveld FC; Macfarlane JD; Bijl H
    Lancet; 1994 Oct; 344(8930):1105-10. PubMed ID: 7934491
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An engineered human antibody to TNF (CDP571) for active Crohn's disease: a randomized double-blind placebo-controlled trial.
    Sandborn WJ; Feagan BG; Hanauer SB; Present DH; Sutherland LR; Kamm MA; Wolf DC; Baker JP; Hawkey C; Archambault A; Bernstein CN; Novak C; Heath PK; Targan SR;
    Gastroenterology; 2001 May; 120(6):1330-8. PubMed ID: 11313302
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tabalumab, an anti-BAFF monoclonal antibody, in patients with active rheumatoid arthritis with an inadequate response to TNF inhibitors.
    Genovese MC; Fleischmann RM; Greenwald M; Satterwhite J; Veenhuizen M; Xie L; Berclaz PY; Myers S; Benichou O
    Ann Rheum Dis; 2013 Sep; 72(9):1461-8. PubMed ID: 23268367
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, for steroid-dependent Crohn's disease: a randomized, double-blind, placebo-controlled trial.
    Feagan BG; Sandborn WJ; Lichtenstein G; Radford-Smith G; Patel J; Innes A
    Aliment Pharmacol Ther; 2006 Mar; 23(5):617-28. PubMed ID: 16480401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).
    Furst DE; Schiff MH; Fleischmann RM; Strand V; Birbara CA; Compagnone D; Fischkoff SA; Chartash EK
    J Rheumatol; 2003 Dec; 30(12):2563-71. PubMed ID: 14719195
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of treatment with a fully human anti-tumour necrosis factor alpha monoclonal antibody on the local and systemic homeostasis of interleukin 1 and TNFalpha in patients with rheumatoid arthritis.
    Barrera P; Joosten LA; den Broeder AA; van de Putte LB; van Riel PL; van den Berg WB
    Ann Rheum Dis; 2001 Jul; 60(7):660-9. PubMed ID: 11406520
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of sirukumab in patients with active rheumatoid arthritis refractory to anti-TNF therapy (SIRROUND-T): a randomised, double-blind, placebo-controlled, parallel-group, multinational, phase 3 study.
    Aletaha D; Bingham CO; Tanaka Y; Agarwal P; Kurrasch R; Tak PP; Popik S
    Lancet; 2017 Mar; 389(10075):1206-1217. PubMed ID: 28215362
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of a novel PEGylated humanized anti-TNF fragment (CDP870) in patients with rheumatoid arthritis: a phase II double-blinded, randomized, dose-escalating trial.
    Choy EH; Hazleman B; Smith M; Moss K; Lisi L; Scott DG; Patel J; Sopwith M; Isenberg DA
    Rheumatology (Oxford); 2002 Oct; 41(10):1133-7. PubMed ID: 12364632
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis.
    Maini RN; Breedveld FC; Kalden JR; Smolen JS; Davis D; Macfarlane JD; Antoni C; Leeb B; Elliott MJ; Woody JN; Schaible TF; Feldmann M
    Arthritis Rheum; 1998 Sep; 41(9):1552-63. PubMed ID: 9751087
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug survival, efficacy and toxicity of monotherapy with a fully human anti-tumour necrosis factor-alpha antibody compared with methotrexate in long-standing rheumatoid arthritis.
    Barrera P; van der Maas A; van Ede AE; Kiemeney BA; Laan RF; van de Putte LB; van Riel PL
    Rheumatology (Oxford); 2002 Apr; 41(4):430-9. PubMed ID: 11961174
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized, double blind, placebo controlled multicenter trial of murine anti-CD4 monoclonal antibody therapy in rheumatoid arthritis.
    Wendling D; Racadot E; Wijdenes J; Sibilia J; Flipo RM; Cantagrel A; Miossec P; Eschard JP; Macro M; Bertin P; Lioté F; Debiais F; Juvin R; Le Goff P; Masson C
    J Rheumatol; 1998 Aug; 25(8):1457-61. PubMed ID: 9712083
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of hyperadiponectinemia following long-term treatment of patients with rheumatoid arthritis with infliximab (IFX), an anti-TNF-alpha antibody.
    Nishida K; Okada Y; Nawata M; Saito K; Tanaka Y
    Endocr J; 2008 Mar; 55(1):213-6. PubMed ID: 18270431
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of an engineered human anti-TNF-alpha antibody (CDP571) on insulin sensitivity and glycemic control in patients with NIDDM.
    Ofei F; Hurel S; Newkirk J; Sopwith M; Taylor R
    Diabetes; 1996 Jul; 45(7):881-5. PubMed ID: 8666137
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized, double-blind, placebo-controlled trial of CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, in patients with corticosteroid-dependent Crohn's disease.
    Feagan BG; Sandborn WJ; Baker JP; Cominelli F; Sutherland LR; Elson CO; Salzberg BA; Archambault A; Bernstein CN; Lichtenstein GR; Heath PK; Cameron S; Hanauer SB
    Aliment Pharmacol Ther; 2005 Feb; 21(4):373-84. PubMed ID: 15709987
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Suppression of fever and the acute-phase response in a patient with juvenile chronic arthritis treated with monoclonal antibody to tumour necrosis factor-alpha (cA2).
    Elliott MJ; Woo P; Charles P; Long-Fox A; Woody JN; Maini RN
    Br J Rheumatol; 1997 May; 36(5):589-93. PubMed ID: 9189062
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.